Mariner
ITCI

Mariner’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mariner’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,921
Closed -$649K – 3736
2025
Q1 		$649K Sell
4,921
-5,576
-53% -$695K ﹤0.01% 1990
2024
Q4 		$877K Buy
10,497
+758
+8% +$62.3K ﹤0.01% 1751
2024
Q3 		$713K Sell
9,739
-519
-5% -$39K ﹤0.01% 1868
2024
Q2 		$703K Sell
10,258
-1,050
-9% -$72.8K ﹤0.01% 1772
2024
Q1 		$783K Buy
11,308
+692
+7% +$47.6K ﹤0.01% 1689
2023
Q4 		$760K Buy
10,616
+954
+10% +$54.9K ﹤0.01% 1639
2023
Q3 		$503K Sell
9,662
-413
-4% -$24.1K ﹤0.01% 1776
2023
Q2 		$638K Buy
10,075
+1,554
+18% +$96.8K ﹤0.01% 1578
2023
Q1 		$462K Buy
8,521
+1,914
+29% +$92.5K ﹤0.01% 1755
2022
Q4 		$350K Buy
6,607
+60
+0.9% +$3.01K ﹤0.01% 1903
2022
Q3 		$305K Buy
+6,547
New +$342K ﹤0.01% 1754

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mariner's ITCI Position: Q2 2025 in Review

Mariner sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,921 shares — an estimated $649K sold.

Mariner first reported a position in ITCI in Q3 2022 and held it in 11 quarters. The position peaked at $877K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Mariner reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 4,921 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $649K.
  • Mariner first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 11 quarters.
  • Mariner's Intra-Cellular Therapies Inc. position peaked at $877K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.